Development of Immune Cell Therapy Using T Cells Generated from Pluripotent Stem Cells

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Mar 12

PMID 38467982

Authors

Hiroshi Kawamoto

Kyoko Masuda

Seiji Nagano

Affiliations

Soon will be listed here.

Abstract

In the field of cancer immunotherapy, the effectiveness of a method in which patient-derived T cells are genetically modified ex vivo and administered to patients has been demonstrated. However, problems remain with this method, such as (1) time-consuming, (2) costly, and (3) difficult to guarantee the quality. To overcome these barriers, strategies to regenerate T cells using iPSC technology are being pursued by several groups in the last decade. The authors have been developing a method by which specific TCR genes are introduced into iPSCs and T cells are generated from those iPSCs (TCR-iPSC method). At present, our group is preparing this approach for clinical trial, where iPSCs provided from the iPSC project are transduced with WT1 antigen-specific TCR that had been already clinically tested, and killer T cells are generated from such TCR-iPSCs, to be administered to acute myeloid leukemia patients. While the adoptive T cell therapies have been mainly directed to be used in cancer immunotherapy, it is possible to apply these approaches to viral infections. Strategies by other groups to regenerate various types of T cells from iPSCs will also be introduced.

References

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

Rosenberg S . Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol. 2011; 8(10):577-85. PMC: 6292196. DOI: 10.1038/nrclinonc.2011.116. View

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S . Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell. 2013; 12(1):31-6. DOI: 10.1016/j.stem.2012.12.006. View

Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S . Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Res. 2016; 76(23):6839-6850. DOI: 10.1158/0008-5472.CAN-16-1149. View

Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H . Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Mol Ther Methods Clin Dev. 2020; 19:250-260. PMC: 7566080. DOI: 10.1016/j.omtm.2020.09.011. View

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S . A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8(5):409-12. DOI: 10.1038/nmeth.1591. View

Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N . Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019; 24(4):566-578.e7. DOI: 10.1016/j.stem.2019.02.005. View

10.

Cheever M, Allison J, Ferris A, Finn O, Hastings B, Hecht T . The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-37. PMC: 5779623. DOI: 10.1158/1078-0432.CCR-09-0737. View

11.

Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 1999; 95(1):286-93. View

12.

Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y . Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017; 130(18):1985-1994. DOI: 10.1182/blood-2017-06-791202. View

13.

Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M . Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. iScience. 2020; 23(4):100998. PMC: 7188741. DOI: 10.1016/j.isci.2020.100998. View

14.

Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T . Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999; 17(9):2859-67. DOI: 10.1200/JCO.1999.17.9.2859. View

15.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

16.

Inoue T, Terada N, Kobayashi T, Ogawa O . Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol. 2017; 14(5):267-283. DOI: 10.1038/nrurol.2017.19. View

17.

Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo T . Efficient Regeneration of Human Vα24 Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo. Stem Cells. 2016; 34(12):2852-2860. DOI: 10.1002/stem.2465. View

18.

Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T . Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013; 12(5):546-58. DOI: 10.1016/j.stem.2013.03.001. View

19.

Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K . Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother. 2011; 60(8):1075-84. PMC: 11029699. DOI: 10.1007/s00262-011-1021-7. View

20.

Watanabe D, Koyanagi-Aoi M, Taniguchi-Ikeda M, Yoshida Y, Azuma T, Aoi T . The Generation of Human γδT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture. Stem Cells Transl Med. 2017; 7(1):34-44. PMC: 5746152. DOI: 10.1002/sctm.17-0021. View